Huaxia Ophthalmology (301267.SZ): Currently, there are no products related to AI glasses.

Gloryunion November 29th | Huaxia Ophthalmology (301267.SZ) stated on the investor interaction platform that the company's main business is ophthalmology medical services, and it is not currently involved in AI eyeglasses related products. The company continues to closely monitor the development of new technologies and products in the ophthalmology industry, actively seeking investment opportunities that align with the company's development global strategy and planning.

Gelonghui FinanceNov 29 15:47

Huaxia Ophthalmology (301267): Income steadily growing, waiting for further acceleration.

In the 1-3Q24, the company achieved revenue/net profit attributable to the parent company of 3.182/0.421 billion yuan (yoy +2.6%/-24.5%), with revenue/net profit attributable to the parent company of 1.131/0.155 billion yuan in 3Q24.

htscOct 29 14:51

Huaxia Ophthalmology: Report for the third quarter of 2024

SZSIOct 29 00:00 · Announcements

Huaxia Ophthalmology (301267.SZ): net income in the first three quarters was 0.421 billion yuan, a year-on-year decrease of 24.49%.

Great Wisdom News on October 28th: Huaxia Ophthalmology (301267.SZ) released its third quarter report for 2024, with a company's revenue of 3.182 billion yuan for the first three quarters, a year-on-year increase of 2.55%; net income attributable to the company's shareholders was 0.421 billion yuan, a year-on-year decrease of 24.49%; net income attributable to the company's shareholders after deducting non-recurring gains and losses was 0.417 billion yuan, a year-on-year decrease of 27.23%; basic earnings per share were 0.50 yuan.

Gelonghui FinanceOct 28 21:50

Huaxia Ophthalmology (301267): Consumer ophthalmology supports steady revenue growth and nationwide chain layout.

The company released its 2024 interim report, with a revenue of 2.051 billion yuan (YoY +2.85%), and a net income attributable to the parent company of 0.265 billion yuan (YoY -25.15%). National chain layout to consolidate scale effects.

國聯證券Sep 2 16:31

Huaxia Eye (301267): Short-term performance under pressure, long-term growth can be expected.

Event: On August 28, the company released its 2024 interim report, achieving revenue of 2.05 billion yuan in the first half of the year, +2.85% YoY, and achieving a net income attributable to shareholders of 0.265 billion yuan, -25.15% YoY.

德邦證券Aug 30 14:11